Suominen’s results turned into sequential decline in Q3 due to operational issues and fell short of ...
Sales -12% and EBIT -2m vs. ABGSCe Weak performance in NW&FT, as market headwinds intensify Expect c...
Sales -6%, adj. EBIT -11% vs. FactSet consensus in Q3 We expect consensus to lower EBIT estimates by...
Redeye raised its asset management assumptions following the strong report with CoinShares Physical ...
Q-linea continues enhancing the pipeline of prospects, from entering tenders to close to the final c...
Redeye updates its estimates and valuation following Freemelt’s Q3 report, which came in above our e...
Redeye makes downward estimate revisions following Climeon’s Q3 report, mainly driven by the absence...
Taaleri's Q3 2024 results were solid on an underlying basis and fairly in line with our estimates.
A weaker-than-expected Q3 on almost all parameters Another PW as extraction of synergies proves cost...
Q3 numbers in line with estimates Guidance trimmed, but limited impact on estimates All share bid li...
Q3: EBITDA of ~NOK 12m, Q4 likely flat New targets achievable, but lower range more likely Recovery ...
Demand weak as expected, but improved by quarter-end Comps also ease in Q4, return to order growth l...
Q3: Revenues 1% below, EBIT DKK -2m vs. ABGSCe +12m FY'24 guidance downgraded again Consensus likely...
Hanza rapporterade ett kvartal över Analysguidens förväntan.
Analyst Group has entered into an agreement with Irisity on commissioned research, including e.
Q3 results in-line, cash burn of DKK 27m Small new design win (~1k units), reiterates target of 4-6 ...
Q3 adj. EBIT of GBP 15m, below ABGSCe at GBP 19m Beat on Asset Management, miss on Capital Markets U...
Q-linea continues improving the pipeline of prospects of various stages, from entering tenders to cl...
Redeye gives its initial comments on the Q3 2024 report from Scandinavian ChemoTech, which was mostl...
Taaleri reported recurring revenues of EUR 9.7m (-6% y/y), 4% below our estimate, mostly explained b...
